GlassScriptPhysician profile
Roshell Tverskaya
NPI 1467221358
$3,920.22
in general payments reported to CMS, 2019-2025
29 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,193 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,915 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,915.22 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $484.76 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $455.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $409.17 | 2024-2025 | Saphnelo |
| Ucb, INC. | $264.17 | 2024-2025 | Bimzelx, Cimzia |
| Organon LLC | $243.48 | 2025 | |
| Arcutis Biotherapeutics, INC. | $222.96 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $213.48 | 2025 | |
| Amgen INC. | $200.82 | 2024-2025 | Evenity, Prolia, Krystexxa |
| Convatec INC. | $171.54 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $160.22 | 2025 | Dupixent, Libtayo |
| Incyte Corporation | $127.92 | 2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $123.48 | 2024-2025 | Orencia |
| Tersera Therapeutics LLC | $86.64 | 2024-2025 | Quzyttir |
| Genzyme Corporation | $83.50 | 2024-2025 | |
| Pfizer INC. | $82.44 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $63.05 | 2024 | Ultomiris, Strensiq |
| Ani Pharmaceuticals, INC. | $56.01 | 2024-2025 | Purified Cortrophin Gel |
| Galderma Laboratories, L.P. | $54.02 | 2025 | Nemluvio |
| Genentech USA, INC. | $52.23 | 2024 | Actemra |
| Strata Skin Sciences, INC. | $48.31 | 2025 | Xtrac |
| Kerecis Limited | $45.88 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Radius Health, INC. | $44.64 | 2024-2025 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $42.27 | 2024 | Arcalyst |
| Lilly USA, LLC | $40.77 | 2024-2025 | Taltz, Ebglyss |
| Botanix Sb INC | $35.58 | 2025 | Sofdra |
| Journey Medical Corporation | $34.51 | 2025 | |
| Leo Pharma INC. | $27.44 | 2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $25.69 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $19.62 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshell Tverskaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.